Clinical reference Biomarker Directory
Back to directory

REN

Established

Renin, paired with aldosterone, is central to diagnosing primary aldosteronism, a common cause of hypertension.

Also known as Renin plasma renin activity direct renin concentration
In plain language

Renin is now at the center of a major shift in how doctors think about high blood pressure: instead of only testing renin and aldosterone in patients with severe or resistant hypertension, leading medical societies are moving toward recommending this test for essentially everyone with high blood pressure, since a hidden hormonal cause turns out to be much more common than previously thought.

Biomarker & context

Renin is an enzyme released by the kidneys that initiates the renin-angiotensin-aldosterone system, ultimately regulating blood pressure and sodium/potassium balance; it is central to diagnosing primary aldosteronism, a common but underdiagnosed cause of hypertension.

What it indicates

Suppressed renin alongside elevated aldosterone (a high aldosterone-to-renin ratio, ARR) indicates primary aldosteronism, in which the adrenal glands produce aldosterone independent of the body's normal renin-driven regulation, causing sodium retention, potassium loss, and treatment-resistant hypertension.

Diagnosis & clinical testing

This is one of the most significant current guideline changes in this entire biomarker set: the Endocrine Society's new 2025 primary aldosteronism guideline moved toward suggesting all hypertensive patients be screened with an ARR — a major shift from the older approach of only testing patients with resistant hypertension, low potassium, or an adrenal mass, reflecting growing recognition that primary aldosteronism is far more common and underdiagnosed than previously believed. The 2024 ESC hypertension guidelines similarly advanced toward universal screening.

Guiding treatment

Confirmed primary aldosteronism is treated with either surgical adrenalectomy (for a unilateral aldosterone-producing adenoma, often curative) or mineralocorticoid receptor antagonists (spironolactone, eplerenone) for bilateral disease, which frequently improves blood pressure control beyond what standard antihypertensives achieve alone.

Clinical significance

A 2025 Endocrine Society guideline shift toward universal hypertension screening represents a major, very current change in practice.

References
  1. Endocrine Society. (2025). Primary Aldosteronism Clinical Practice Guideline.
  2. PMC. (2025). Universal Screening for Primary Aldosteronism in Hypertensive Patients: A 2025 Taipei Positional Paper.